PMID- 27877014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1000-9604 (Print)
IS  - 1993-0631 (Electronic)
IS  - 1000-9604 (Linking)
VI  - 28
IP  - 5
DP  - 2016 Oct
TI  - Prognostic potential of an immune score based on the density of CD8(+) T cells, 
      CD20(+) B cells, and CD33(+)/p-STAT1(+) double-positive cells and HMGB1 
      expression within cancer nests in stage IIIA gastric cancer patients.
PG  - 543-552
AB  - OBJECTIVE: There is heterogeneity in the prognosis of gastric cancers staged 
      according to the tumornodes- metastasis (TNM) system. This study evaluated the 
      prognostic potential of an immune score system to supplement the TNM staging 
      system. METHODS: An immunohistochemical analysis was conducted to assess the 
      density of T cells, B cells, and myeloid-derived suppressor cells (MDSCs) in 
      cancer tissues from 100 stage IIIA gastric cancer patients; the expression of the 
      high-mobility group protein B1 (HMGB1) was also evaluated in cancer cells. The 
      relationship between the overall survival (OS), disease-free survival (DFS), and 
      immunological parameters was analyzed. RESULTS: An immune score system was 
      compiled based on the prognostic role of the density of T cells, B cells, MDSCs, 
      and the expression of HMGB1 in cancer tissues. The median 5-year survival of this 
      group of patient was 32%. However, the 5-year survival rates of 80.0%, 51.7%, 0%, 
      5.8%, and 0% varied among the patients with an immune score of 4 to those with an 
      immune score of 0 based on the immune score system, respectively. Similarly, 
      differences in DFS rates were observed among the immune score subgroups. 
      CONCLUSIONS: An immune score system could effectively identify the prognostic 
      heterogeneity within stage IIIA gastric cancer patients, implying that this 
      immune score system may potentially supplement the TNM staging system, and help 
      in identifying a more homogeneous group of patients who on the basis of prognosis 
      can undergo adjuvant therapy.
FAU - Dong, Jun
AU  - Dong J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Biotherapy Center, Sun Yat-Sen University Cancer Center, 
      Guangzhou 510060, China; Department of Oncology.
FAU - Li, Jiao
AU  - Li J
AD  - Department of Cardiology, The Second Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou Institute of Cardiovascular Disease, Guangzhou 510260, 
      China.
FAU - Liu, Shiming
AU  - Liu S
AD  - Department of Cardiology, The Second Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou Institute of Cardiovascular Disease, Guangzhou 510260, 
      China.
FAU - Feng, Xingyu
AU  - Feng X
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Biotherapy Center, Sun Yat-Sen University Cancer Center, 
      Guangzhou 510060, China.
FAU - Chen, Shi
AU  - Chen S
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Department of Gastric & Pancreatic Surgery, Sun Yat-Sen 
      University Cancer Center, Guangzhou 510060, China.
FAU - Zhou, Zhiwei
AU  - Zhou Z
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Biotherapy Center, Sun Yat-Sen University Cancer Center, 
      Guangzhou 510060, China.
FAU - Chen, Yingbo
AU  - Chen Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Department of Gastric & Pancreatic Surgery, Sun Yat-Sen 
      University Cancer Center, Guangzhou 510060, China.
FAU - Zhang, Xiaoshi
AU  - Zhang X
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      of Cancer Medicine; Biotherapy Center, Sun Yat-Sen University Cancer Center, 
      Guangzhou 510060, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Cancer Res
JT  - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
JID - 9315242
PMC - PMC5101229
OTO - NOTNLM
OT  - B cell
OT  - CD33
OT  - Immune score
OT  - STAT1
OT  - T cell
OT  - gastric cancer
OT  - high-mobility group protein B1 (HMGB1)
EDAT- 2016/11/24 06:00
MHDA- 2016/11/24 06:01
PMCR- 2016/10/01
CRDT- 2016/11/24 06:00
PHST- 2016/11/24 06:00 [entrez]
PHST- 2016/11/24 06:00 [pubmed]
PHST- 2016/11/24 06:01 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - cjcr-28-5-543 [pii]
AID - 10.21147/j.issn.1000-9604.2016.05.10 [doi]
PST - ppublish
SO  - Chin J Cancer Res. 2016 Oct;28(5):543-552. doi: 
      10.21147/j.issn.1000-9604.2016.05.10.